Becton, Dickinson and Company (NYSE: BDX) — The Dividend King Whose Moats Don’t Reach the Owner

Independent fundamental research — fresh coverage Sector: Health Care — Medical Devices, Consumables & Diagnostics (MedTech) · CIK: 0000010795 · FY-end: September 30 · Report date: 2026-06-19 Price referenced: ~$144 (close 2026-06-18) · Market cap: ~$41B · Enterprise value (pre-separation FY25 basis): ~$61B

⚡ Claude’s Take

This block is the author’s own independent opinion and general information only — not investment advice and not a recommendation to buy or sell any security. The analysis that follows takes no position and carries no price target.

Verdict: HOLD / accumulate-on-weakness for income-and-value patience — not a high-conviction buy. Fair-value zone ~$150–$185 (≈12–14.5× New-BD FY26 adjusted EPS of ~$12.6); a margin-of-safety entry is the low-$130s–$140s, i.e., right about here. Conviction: medium. Tag: “A great franchise the owner overpaid to assemble.”

Becton Dickinson is the rarest combination in MedTech: a portfolio of genuinely irreplaceable franchises — the world’s blood-collection-tube standard (BD Vacutainer), the #1 pre-fillable-syringe supplier to pharma (serving 27 of the top 30 drugmakers, now riding the GLP-1/biologics wave), and the Pyxis dispensing installed base — wrapped around a balance sheet that earns its owners almost nothing. The defining number in this report is not revenue or margin; it is return on invested capital stuck at ~5.5–6% for five straight years, barely at the cost of capital, because BD bought its moats (CareFusion at ~$12.6B, C.R. Bard at ~$24B / ~21× EBITDA, Edwards Critical Care at ~$3.9B) at full prices funded with stock and debt. The moats are real for the business; they have not been real for the shareholder. That is the whole story, and it is why a company with 36–43% segment operating margins trades at ~11× EV/EBITDA and the 4th percentile of its own decade of price-to-sales — a discount to every quality MedTech peer except a visibly broken Baxter.

What gets me to HOLD-leaning-constructive rather than AVOID is that the value-recovery machinery is finally turning: the Waters Reverse-Morris-Trust separation (closed Feb 9, 2026) sheds the slow-growth Diagnostics drag and hands BD ~$4B to delever and buy back stock; Starboard is in the door; the Alaris recall is behind it; and management raised the post-separation EPS guide at Q2 FY26 after years of cuts. The market is pricing BD as a structurally-challenged, over-levered serial-disappointer — which it has been — and is under-pricing the optionality that a focused, deleveraging “New BD” with a fortress 53-year dividend and a real GLP-1 tailwind could re-rate even one or two turns. What flips me decisively bullish: ROIC inflecting above ~8% as Bard/CareFusion intangible amortization rolls off and organic growth re-accelerating to mid-single-digits. What flips me bearish: a China-VBP-plus-oral-GLP-1 squeeze on the two best franchises, or an EtO/PowerPort litigation surprise that breaches the ~$1.7B reserve. This is a coiled-spring value-and-income name for the patient, not a compounder you chase.

📈 Stock Price Action — Five-Year Event Map

Factual price history (split/dividend-adjusted, AZI series). Price moves are FACT; attributed drivers are INTERPRETATION. No recommendation, no target.

BDX has round-tripped a full cycle of hope and disappointment. On the adjusted series the stock ran from ~$173 (Sep-2021) to a ~$210 peak (Jul-2023), then de-rated hard to a ~$126 trough by May-2025 as organic growth repeatedly disappointed, before the activist/separation narrative carried it back to a ~$183 52-week high (Feb-2026). It has since slid ~21% to ~$144 — roughly 31% below its mid-2023 high and only ~14% above the 2025 low. The five-year arc is a textbook event-driven name: an operational/regulatory de-rating, an activist-fueled re-rating, then the math of a smaller standalone company reasserting itself.

The pattern: the 2023–2025 leg was a genuine fundamental/regulatory de-rating; the 2025–early-2026 ramp was activist optimism; and the current pullback is the arithmetic of a lower-absolute-EPS, ~3.4×-levered standalone reasserting itself over that optimism.

1. Executive Summary

Becton, Dickinson and Company is a 128-year-old MedTech franchise that makes the consumable backbone of modern healthcare delivery: syringes and needles, IV catheters, the BD Vacutainer blood-collection tubes that are a de-facto global standard, BD Pyxis automated medication dispensing and BD Alaris infusion pumps, pre-fillable glass syringes sold to the pharmaceutical industry, and a portfolio of interventional devices (urology, peripheral, surgery) acquired with C.R. Bard. FY2025 revenue was $21.84B (+8.2% reported, but only +2.9% organic), gross margin 45.4%, GAAP operating margin 13.7%, EBITDA $5.45B (24.9% margin), GAAP EPS $5.82, and adjusted EPS $14.40. Operating cash flow was $3.43B and free cash flow roughly $2.5B.

The investment tension is unusually clean. At the operating level, BD looks like a high-quality compounder — segment operating margins of 36–43%, category leadership in nearly everything it sells, recurring consumable revenue, and a 53-year dividend-increase streak (a Dividend King). At the capital level, it has been a poor business for its owners — return on invested capital of ~5.5–6% for five consecutive years, return on equity of ~10%, return on assets of ~3%, and negative tangible common equity (~−$10.6B), because ~$36B of goodwill and intangibles sit on the balance sheet from acquisitions BD overpaid for. Purchase-accounting amortization alone (~$1.9B/yr) nearly equals pretax income. The moats are durable; the price BD paid to assemble them destroyed economic value, exactly as Marathon’s capital-cycle framework would predict for a debt-and-stock-funded roll-up bought at peak multiples.

The company is now dismantling the conglomerate it spent a decade building. It spun off diabetes (embecta, 2022) and, on February 9, 2026, completed a Reverse Morris Trust separation of its Biosciences and Diagnostic Solutions businesses into Waters Corporation, leaving a focused “New BD” of roughly $16–17B revenue across four segments (Medical Essentials, Connected Care, BioPharma Systems, Interventional). The separation hands BD ~$4B of cash (earmarked for deleveraging and buybacks) and removes the slow-growth Diagnostics drag — but it also sheds BD’s market-leading flow-cytometry franchise and resets standalone adjusted EPS to ~$12.6 (FY26 guide $12.52–$12.72, raised at Q2 after years of cuts).

The stock, at ~$144, trades at ~11× EV/EBITDA, ~11.4× forward New-BD adjusted EPS, and the 4th percentile of its own 10-year price-to-sales range — a discount to every quality MedTech peer (MDT 14.7×, ABT 19.0×, BSX 18.7×, SYK 21.7× EV/EBITDA) except a visibly distressed Baxter (14.1×). The market is pricing BD as a low-growth, over-levered serial disappointer. The variant question is whether a focused, deleveraging New BD — with a fortress dividend, a genuine GLP-1/biologics pre-fillable-syringe tailwind, and ~$36B of value-suppressing intangibles slowly amortizing off — can inflect ROIC and organic growth enough to earn a re-rating. The bull and bear both rest on the same axis: does the business’s quality finally reach the owner, or do the moats remain real but irrelevant to shareholders? (No recommendation or price target in this body; see Claude’s Take above for the single labeled opinion.)

2. Business Overview

What BD does. Becton Dickinson develops, manufactures and sells medical devices, instruments, consumables, reagents and diagnostic products to hospitals, clinical laboratories, the pharmaceutical industry, physician offices and researchers worldwide. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, it employs ~70,000 people and generated $21.84B of revenue in FY2025. The defining economic feature of the business is that the large majority of revenue is recurring consumables — single-use syringes, needles, catheters, blood-collection tubes, IV sets, reagents and pre-fillable syringes — sold into installed bases of capital equipment (dispensing cabinets, infusion pumps, flow cytometers). This is a razor/razorblade model at industrial scale: BD ships billions of units per year of products that are consumed and re-ordered.

Segment structure — a moving target. BD has reorganized twice in two years, so the memo carries both views:

• FY2025 (as reported): three legacy segments — BD Medical ($11,456M revenue, 36.1% segment operating margin), BD Life Sciences ($5,167M, 31.8%), and BD Interventional ($5,217M, 43.2%).
• “New BD” (post-Feb-2026, four segments): Medical Essentials (Medication Delivery Solutions + Specimen Management — syringes/needles/catheters and BD Vacutainer tubes); Connected Care (Medication Management Solutions/Pyxis-Alaris + Advanced Patient Monitoring/Edwards); BioPharma Systems (pre-fillable syringes to pharma); and Interventional (Urology & Critical Care, Peripheral Intervention, Surgery). The old Life Sciences segment — Biosciences (flow cytometry) and Diagnostic Solutions — departed to Waters Corporation on February 9, 2026. Diabetes Care had already been spun off as embecta in April 2022.

Revenue by organizational unit (FY2025, $M): Medication Delivery Solutions $4,575; Medication Management Solutions (Pyxis/Alaris) $3,474; Pharmaceutical/BioPharma Systems $2,324; Advanced Patient Monitoring (Edwards, first full year) $1,082; Specimen Management $1,871; Peripheral Intervention $1,996; Urology & Critical Care $1,649; Surgery $1,572; and the departing Diagnostic Solutions $1,838 and Biosciences $1,458.

Geography. US $12,790M (58.6%); International $9,049M (41.4%), within which EMEA ~21.7%, Greater Asia ~14.2% (including China, which BD does not break out separately — estimated ~5–6% of revenue), and the rest Latin America/Canada. The heavy ex-US mix (~41%) brings recurring FX translation noise and direct exposure to China’s volume-based procurement (VBP) tenders.

How it makes money. Four economic engines: (1) commodity consumables (syringes, needles, basic catheters) — enormous volumes, thin differentiation, GPO/VBP price pressure; (2) standard-setting consumables (BD Vacutainer blood tubes) — near-monopoly, validated into lab workflows; (3) installed-base razor/razorblade (Pyxis dispensing cabinets and Alaris pumps placed into hospitals, pulling through dedicated disposables, software and service over multi-year lives); and (4) long-cycle contract supply (pre-fillable syringes qualified into pharma drug filings). The blend is defensive and recurring, but it is weighted toward the slower, more price-pressured end of MedTech relative to a Stryker (orthopedics) or Edwards (structural heart).

Verdict: A broad, defensive, recurring-revenue consumables-and-devices franchise with category leadership across most of its portfolio — but a blended business mix tilted toward mature, price-pressured categories, now being deliberately narrowed via separations. High-quality cash generation; mid-single-digit growth ceiling.

3. Industry Dynamics

Structure. The global medical-device, consumables and diagnostics industry is large (~$500B+), grows mid-single-digits, and is consolidated at the top while fragmented across thousands of product niches. It is structurally attractive on most axes: secular demand from aging demographics and rising procedure volumes; high regulatory barriers to entry (FDA 510(k)/PMA in the US, EU MDR/IVDR in Europe); sticky recurring consumables; and rational oligopolies in the better niches. BD’s own 10-K, however, flags two structural negatives candidly: the industry “has experienced a significant amount of consolidation, resulting in companies with greater scale than BD,” and hospital/IDN consolidation “has increased customer purchasing power.”

BD’s category positions and their market growth:

• Blood-collection tubes (BD Vacutainer): BD is the dominant global supplier; market ~6% CAGR. Competitors (Greiner Bio-One, Sarstedt, Terumo) are distant. Tubes are validated into analyzer/LIS workflows, making switching a whole-lab re-validation exercise.
• Pre-fillable syringes: ~$8.7B (2025) growing ~9.7% CAGR to ~$18B by 2033. BD is #1 (Gerresheimer #2, then SCHOTT, West, Terumo). BD ships >3 billion syringe barrels/yr. This is the industry’s most attractive niche and the structural beneficiary of injectable GLP-1/biologics demand.
• Flow cytometry (departing to Waters): ~$5.1B growing ~8.7%; BD was market leader ahead of Beckman Coulter (Danaher), Thermo Fisher, Sony, Cytek.
• Automated medication dispensing (Pyxis): ~22–26% share, #1; Omnicell #2.
• Infusion pumps (Alaris): historically top-2/3 in the US alongside ICU Medical (which absorbed Smiths Medical) and Baxter.

Regulation and reimbursement. FDA quality-system oversight is a live, recurring cost and risk for BD specifically (see the Risk Analysis section). EU MDR (2017/745) and IVDR (2017/746) impose stricter clinical-evidence and quality-system requirements with multi-year recertification burden; BD discloses recurring “European regulatory initiative-related costs” of roughly $100M+/yr. On the demand side, most BD products are reimbursed indirectly (bundled into hospital DRG payments rather than separately billed), which insulates volumes but caps pricing.

Pricing power and the buy side. BD sells largely through GPOs and into consolidated IDNs, a structural source of pricing pressure on the commodity end. China VBP — government tenders that compress prices on commodity devices — is the most acute threat and is cited every quarter. Offsetting these: scale, breadth (a one-stop med-surg catalog), and switching costs in the installed-base franchises.

Capital-cycle read (Marathon lens). The high-return niches are attracting capital: Gerresheimer and SCHOTT are expanding pre-fillable-syringe capacity for the GLP-1 wave, and BD itself announced a $110M US capacity investment (Jan-2026). Supply will respond to the one genuinely high-return tailwind BD has — a reminder that even the best franchise faces mean reversion in returns as capacity builds.

Verdict: structurally good industry, but BD’s blended exposure is below-average within it. Secular demand, high barriers, and recurring consumables make MedTech attractive in aggregate; but BD’s mix skews toward mature, GPO/VBP-pressured commodity categories, and customer consolidation is shifting power toward buyers. A good industry, with BD positioned toward its slower, more price-competitive end.

4. Competitive Position

The right way to assess BD’s moat is franchise-by-franchise in Greenwald’s taxonomy, because the answer differs sharply across the portfolio — and because the consolidated returns data tells you the moats, while real, do not reach the owner.

The Alaris case study — proof the moats are conditional on execution. Alaris (acquired with CareFusion) sat under an FDA consent decree; following 2019–2020 Class I recalls, BD voluntarily pulled it from the US market and did not regain 510(k) clearance until July 2023 — roughly three years off the market. The switching-cost moat held the existing installed base reasonably well (hospitals did not rip Alaris out), but BD lost the flow of new placements to ICU Medical and Baxter, paid a $175M SEC settlement (Dec-2024) over its disclosure of the issue, and incurred years of remediation cost. The episode demonstrates that BD’s moats are vulnerable not just to competitors but to BD’s own quality-system failures — a theme that recurs in the two open FDA Warning Letters today (see Risk Analysis).

The decisive evidence — moats that don’t earn for the owner. BD passes Greenwald’s tests at the operating-margin and market-share-stability level: 36–43% segment margins, durable #1/#2 positions, stable share. But it fails the ROIC test that matters to a shareholder. Consolidated ROIC has been ~5.5–6.0% for five straight years; ROE ~10%; ROA ~3%. The reason is not weak franchises — it is that BD purchased most of these moats (CareFusion, Bard, Edwards) at prices that capitalized away their excess returns, leaving ~$36B of goodwill/intangibles whose ~$1.9B/yr amortization consumes nearly all pretax income. A moat the acquirer overpays for does not show up in the acquirer’s returns.

Versus peers. Stryker (SYK) and Boston Scientific (BSX) are structurally higher-growth and higher-ROIC, which is why they command 18–22× EBITDA. Medtronic (MDT) is a closer analog — large, mature, mid-single-digit growth — and trades at 14.7×. Abbott (ABT) blends diagnostics, devices and nutrition at 19×. Edwards (EW) sold its Critical Care unit to BD and remains a higher-growth structural-heart pure-play. BD’s discount to all of them reflects its lower growth and its capital-return problem.

Verdict: genuine, durable competitive advantages in 3–4 franchises (Vacutainer, pre-fillable syringes, Pyxis, flow-cytometry-departing) — but a mediocre return-on-capital business for the owner. The moat is real; its excess returns have been paid away in acquisition prices. That gap is the thesis, and it is the most important thing to underwrite.

5. Growth History and Forward Opportunities

History — low-quality, acquisition-padded, decelerating. Reported revenue: FY2021 $20.25B → FY2022 $18.87B (embecta spin) → FY2023 $19.37B → FY2024 $20.18B → FY2025 $21.84B. The headline FY2025 +8.2% looks healthy, but organic growth was only +2.9% — well below BD’s own ~mid-single-digit target — with the rest coming from the Edwards/APM acquisition (~5 points) and FX. The pattern across the period is the same: BD has hit adjusted EPS growth (FY2025 +9.6%) through margin programs, buybacks and acquired revenue rather than organic volume. This is the Marathon “growth-through-acquisition” tell that precedes weak returns on capital — and BD’s flat ~5.5% ROIC confirms it.

Segment color (FY2025 organic): BD Medical +13.6% — but almost entirely the APM/Edwards acquisition; ex-APM Medical was low-single-digit. BD Life Sciences −0.6% — the drag, as Diagnostic Solutions declined on COVID/respiratory-testing normalization (now departing to Waters; BD is selling its weakest grower together with its best-share franchise). BD Interventional +4.6% — the best organic performer, led by double-digit PureWick (urology) and Rotarex atherectomy, partly offset by China VBP in Peripheral Intervention.

Forward drivers — mixed, improving in mix:

1. BioPharma Systems / GLP-1 and biologics (the highest-quality driver, FACT). Injectable GLP-1 and biologic demand structurally lifts pre-fillable-syringe volumes (BD Neopak syringes, BD Vystra GLP-1 pen); the market compounds ~9.7% to ~$18B by 2033. BD announced a $110M US capacity investment (Jan-2026) and cites high-single-digit Biologics growth. Caveat: the 10-K explicitly names oral GLP-1 as a competitive/obsolescence risk — a mass shift from injectable to oral formulations would blunt this tailwind over time.
2. Alaris recovery (FACT). Remediation completing into FY2026 with an EMR-interoperable system rolling out; this is recovery toward prior position, not net-new growth.
3. Advanced Patient Monitoring (Edwards Critical Care). Double-digit growth in its first full years; adds hemodynamic monitoring to Connected Care.
4. “BD Excellence” margin/EPS program — the operating system underpinning the adjusted-margin expansion the equity story rests on.

Headwinds (FACT): China VBP and anti-corruption (persistent low-single-digit drag); tariffs (~160 bps gross-margin hit in Q2 FY26, only partly offset by productivity); EU MDR/IVDR recertification cost; and the structural decline in the departing Diagnostics business.

The separation reshapes the growth profile. Shedding Diagnostics (declining) sharpens New BD’s growth mix, but it also sheds flow cytometry (a good, ~8.7%-growth franchise) and resets standalone adjusted EPS to ~$12.6. New-BD Q1 FY26 adjusted EPS was $2.91 (−15.2% YoY) on lost high-margin earnings and not-yet-eliminated stranded costs — a near-term overhang. Management’s FY26 New-BD guide is low-single-digit revenue growth and $12.52–$12.72 adjusted EPS (≈6% growth at midpoint), raised at Q2 — a credibility positive after years of cuts.

Verdict: historically low-quality growth, improving in focus. Organic growth decelerated to sub-3% and EPS was manufactured via M&A, margins and buybacks; the forward picture is genuinely mixed-but-better — the GLP-1/biologics tailwind and Alaris recovery are real, the portfolio is sharper post-separation, but New BD carries an EPS reset and a mid-single-digit growth ceiling.

6. Financial Quality

Revenue and margins. FY2025 revenue $21.84B at 45.4% gross margin (up from 42.2% in FY2023 as Alaris/inflation pressures eased). GAAP operating margin was 13.7% and EBITDA margin 24.9% — but the gap between GAAP operating income ($2.99B) and the ~36% segment operating margins is the ~$2.6B of unallocated corporate cost plus ~$1.9B of acquisition amortization. The single most important quality flag is that purchase-accounting amortization (~$1.9B/yr) nearly equals pretax income ($1.88B). This is why GAAP EPS ($5.82) is less than half of adjusted EPS ($14.40): the adjustments are dominated by real, recurring acquired-intangible amortization and deal/integration/litigation charges. Investors should treat neither figure naively — GAAP understates cash economics (amortization is non-cash), but adjusted EPS flatters by stripping out the genuine, repeating cost of BD’s acquisition strategy.

Cash flow. Operating cash flow was $3.43B in FY2025; with capex of roughly $0.9B, free cash flow was ~$2.5B — a ~6% FCF yield on the current ~$41B market cap. FCF/net-income conversion looks high (~2.0×) precisely because of the large non-cash amortization add-back. FCF has been steady at $2.5–3.0B (ex the COVID-inflated FY2021 $4.6B), comfortably covering the ~$1.2B dividend with room for buybacks and debt paydown.

Returns on capital — the crux. ROIC ~5.9% (FY2025), ROE ~10.0%, ROA ~3.0%. These are low for a business with 36–43% segment margins, and the explanation is entirely the denominator: ~$36B of goodwill/intangibles ($26.6B goodwill + $9.4B intangibles) against $25.4B of total equity, producing negative tangible common equity of ~−$10.6B. The good news embedded here: as the Bard/CareFusion intangibles amortize off over the coming years (~$1.9B/yr), invested capital and the amortization drag both fall, which should mechanically lift GAAP ROIC and EPS even with flat operating performance — a slow tailwind the bull case leans on.

Balance sheet and leverage. Total debt $19.2B, cash $0.6B → net debt ~$18.5B, roughly 3.4× EBITDA, at a 3.4% weighted cost of debt. Ratings are mid-investment-grade (S&P BBB / Moody’s Baa2 / Fitch BBB, all stable). Interest expense has risen ($452M FY23 → $613M FY25) with rates and the Edwards debt. The ~$4B Waters cash distribution (used ~$2B ASR / ~$2B debt paydown) modestly improves the post-separation position, but on a smaller EBITDA base the leverage ratio does not fall dramatically. The balance sheet is the binding constraint on capital returns and the reason BD has limited room for another large deal without a downgrade.

Working capital. Cash conversion cycle ~110 days (inventory-heavy, as a global consumables manufacturer); FY2025 saw an $800M working-capital outflow (inventory build, prepaid). Nothing alarming, but not a source of cash either.

Verdict: high-quality cash generation and margins at the operating level; mediocre returns on the capital actually deployed. Economics are good per unit of operating capital but poor per dollar invested, because of the acquisition-loaded balance sheet. The thesis hinges on whether amortization roll-off and deleveraging close that gap.

7. Capital Allocation

This is the heart of the BDX story, and the record is, on balance, value-destructive at the per-share level — an assessment the current restructuring implicitly concedes.

The M&A track record.

• CareFusion (2015, ~$12.6B): brought Pyxis dispensing and Alaris infusion pumps — the foundation of today’s Connected Care. Strategically the more successful of the two mega-deals (Pyxis is a genuine switching-cost franchise), but it imported the Alaris consent-decree/recall liability that cost BD three years of market absence and a $175M SEC settlement.
• C.R. Bard (Dec-2017, ~$24B at $317/share, ~21.4× LTM EBITDA): the transformational, leverage-and-dilution-defining deal that created BD Interventional. Funded with ~$13B cash/debt plus BD stock and mandatory convertibles. It created ~$16.6B goodwill + ~$12.1B intangibles — the origin of today’s balance sheet. Eight years on, with consolidated ROIC ~6%, the math says Bard has not cleared its cost of capital. This is the textbook Marathon value-destruction pattern: a peak-multiple, asset-growth-driven acquisition after which returns on capital fell and the stock de-rated.
• Edwards Critical Care / Advanced Patient Monitoring (Sept-2024, $3.914B fair value): all-cash, debt-funded just before the separation; contributed $1,082M in FY2025 with double-digit growth. Strategically coherent but added leverage at an inopportune moment, and one year of data is too little to judge returns.
• Bolt-ons and divestitures: Parata Systems (pharmacy automation, 2022, $1.525B); numerous small tuck-ins; embecta diabetes spin-off (2022); V. Mueller surgical instrumentation divested.

The dilution scar. Diluted share count went from ~265M (FY2018) to a ~292M peak (FY2021) — a ~10% permanent increase to fund Bard — and has only edged back to ~285M (FY2025) despite billions of buybacks, because SBC and ASR mechanics offset. A decade of M&A added net shares; buybacks have barely dented them.

Shareholder returns. The dividend is the genuinely well-managed piece: $4.16/share in FY2025, ~$1.2B/yr, ~71% of GAAP but only ~30% of adjusted EPS, with a 53-year increase streak (Dividend King). It is durable and well-covered on a cash basis — and the reason BD attracts low-vol/quality-income holders. Buybacks, by contrast, were absent for years and only restarted under activist pressure: $0 (FY2023) → $500M (FY2024) → $1.0B (FY2025) → continuing in FY2026, with a 10M-share authorization approved January 2025 — the step-up tracking Starboard’s arrival, not proactive conviction.

Incentives (FY2025 proxy). CEO/Chairman/President Tom Polen earned ~$17.1M (stable). The annual bonus weights Revenues 40% / Adjusted EPS 20% / Operating Margin 20% / FCF Conversion 20%; the LTI is 50% performance units (split Revenue Growth 50% / ROIC 50%, with a ±20% relative-TSR modifier) + 25% SARs + 25% time-vested units. The presence of ROIC and relative TSR in the LTI is genuinely good — it targets the exact metric BD has failed on. But the heavy weighting on Revenue and adjusted EPS can reward the acquired-growth behavior that destroyed per-share value, and the 2022–2024 performance units paid out at 137% of target while ROIC sat at ~6% and the stock de-rated — suggesting soft targets. Say-on-pay support was ~89% (decent, not a ringing endorsement).

Insider conviction is thin. Over 24 months the Form 4 record shows only two open-market purchases, both by directors — Greg Hayes (5,250 shares at ~$191.57, ~$1.0M, Aug-2025) and Jeffrey Henderson (1,500 at ~$233.62, Feb-2025) — and zero open-market buys by the CEO or CFO. The director buys are a modest positive (both bought well above today’s price), but the absence of management buying for a stock the board calls undervalued is a notable silence.

Verdict: largely poor capital allocation at the per-share level — and the separations are the correction. Competent operators built scale and sticky positions but paid away their value, leaving negative tangible equity and ~6% ROIC. The Embecta and Waters separations are management dismantling the conglomerate it built — the right corrective action and the first real chance to delever and shrink the float from a position of strength, but value recovery, not value creation. The forward thesis depends on execution that has not yet happened.

8. Changes and Headwinds — Last Two Years

The two-year arc is a deliberate portfolio reshaping: acquire growth (Edwards Critical Care, Sept-2024) → respond to an activist (Starboard, Feb-2025) → separate the slow-growth Life Sciences businesses into Waters (announced Jul-2025, closed Feb-9-2026) → buy back stock and delever with the ~$4B proceeds.

• Starboard Value (Feb-2025): disclosed a stake and publicly pushed for the Biosciences/Diagnostics separation — into which BD essentially announced its own review in parallel. Notably, there is no evidence of a board-seat cooperation agreement or Starboard-nominated directors — an unusually non-contested, aligned campaign (“pushing an open door”).
• Waters Reverse Morris Trust (announced Jul-13-2025, closed Feb-9-2026): BD’s Biosciences + Diagnostic Solutions combined with Waters; BD shareholders own ~39.2% of the combined company, Waters holders ~60.8%; BD received a ~$4B cash distribution and Waters assumed ~$4B incremental debt. Generally tax-free. New BD becomes a focused medtech of ~$16–17B revenue.
• FY2026 segment realignment into the four New-BD segments, plus a new international structure.
• Recent results: Q1 FY26 (reported Feb-9-2026, the day the deal closed) — total revenue $5.3B, New-BD +2.5% FX-neutral, adjusted EPS $2.91, and the introduction of the New-BD $12.35–$12.65 guide. Q2 FY26 (May-7-2026) — revenue $4.7B (+2.6% FX-neutral), adjusted EPS $2.90 (beat ~$2.78 consensus), adjusted operating margin 24.2%, but a GAAP net loss of $(311)M on separation/discontinued-operations charges, and guidance raised to $12.52–$12.72. Gross margin took ~160 bps of tariff pressure.

Headwinds carried forward: tariffs (structural ~160 bps gross-margin drag), China VBP and weak vaccine demand, stranded costs from the separation (not fully eliminated), the GAAP/adjusted credibility gap (a GAAP loss quarter the same year as a $175M SEC disclosure settlement), and ~3.4× leverage on a smaller post-spin EBITDA base.

Verdict: net-positive direction, unproven execution. The moves create a higher-growth, higher-margin, more focused pure-play with cash to delever and buy back — but they leave stranded costs, integration/dis-integration risk, and a balance sheet still doing the heavy lifting. The reshaping strengthens the long-term thesis while adding near-term noise and a lower absolute EPS base.

9. Risk Analysis

BD’s risk profile is dominated by inherited Bard litigation, a pattern of FDA quality-system findings, and the structural pressures on its slower franchises.

Catastrophic-loss risk is low. BD is a diversified, investment-grade, cash-generative consumables franchise with a fortress dividend; a total or near-total permanent loss is hard to construct absent a balance-sheet shock. The realistic downside is de-rating plus litigation cash bleed — a multi-year dead-money outcome if ROIC and growth fail to inflect and the EtO/PowerPort torts breach the reserve — rather than impairment of the going concern.

10. Valuation Discussion (Embedded Expectations)

Where the stock trades. At ~$144, BD’s market cap is ~$41B and, on the FY2025 (whole-company) basis, EV ~$61B → ~11.2× EV/EBITDA, ~2.6–2.8× EV/sales, ~12× P/FCF. On the forward New-BD adjusted EPS of ~$12.6, the P/E is ~11.4×. Most tellingly, on its own 10-year history BD sits at the 4th percentile of price-to-sales and the 7th percentile of price-to-book (AZI own-history valuation index) — i.e., close to the cheapest it has ever been on sales and book — with an 11-year EV/EBITDA range of ~11–19× and the stock now at the bottom of it.

Versus peers (TTM EV/EBITDA). BDX 11.2× is a clear discount to the quality MedTech group: Medtronic 14.7×, Abbott 19.0×, Boston Scientific 18.7×, Stryker 21.7×. The only comparable name is a visibly distressed, deleveraging Baxter at 14.1× (whose EV/EBIT of ~88× signals broken earnings). The discount is partly deserved — BD grows slower than BSX/SYK and carries more leverage and a worse ROIC than ABT/SYK — but the gap to the closest analog, Medtronic, is ~3.5 turns of EBITDA for businesses of broadly similar growth and margin profile.

Embedded expectations — what the price implies. At ~11.4× forward earnings with a ~6% FCF yield and a 2.6% dividend yield, the market is underwriting: low-single-digit revenue growth, no ROIC inflection, continued litigation cash bleed, and no multiple re-rating — essentially extrapolating the serial-disappointer history. A simple scenario frame on New-BD adjusted EPS (~$12.6 base, growing):

• Bear (~$120–135): organic growth stalls below 2%, China VBP + oral-GLP-1 pressure the best franchises, an EtO/PowerPort surprise hits cash, ROIC stays ~6%; the stock holds ~10–11× a flat ~$12.5–13 EPS. Dead money with a covered dividend.
• Base (~$150–185): New BD grows revenue ~mid-single-digits and adjusted EPS ~6–8%/yr, deleveraging proceeds, amortization roll-off lifts GAAP ROIC toward ~7–8%, and the multiple re-rates modestly toward Medtronic’s ~13–14× on ~$13.5–14 EPS.
• Bull (~$200+): the GLP-1/biologics tailwind compounds high-single-digits in BioPharma, Alaris fully recovers, buybacks shrink the float meaningfully with the Waters cash, ROIC inflects through 8%, and BD re-rates to a mid-teens multiple as a focused pure-play — the “self-help works” outcome.

The valuation is not demanding; the question is whether it’s a value trap. BD is cheap on every absolute and own-history measure, with a well-covered Dividend-King payout providing a floor. The risk is the classic one for a low-ROIC, mature compounder: cheapness can persist for years if growth and returns never inflect. The embedded expectations are low enough that modest execution — holding mid-single-digit growth and proving the deleveraging/amortization-roll-off ROIC story — would be rewarded. No price target; the scenario zones above are illustrative of embedded expectations, not a recommendation.

11. Variant Perception

Consensus view. BD is a low-growth, over-levered, litigation-burdened serial disappointer with a great dividend — a defensive bond-proxy that has earned its discount and whose break-up is a “show-me” story. The tape agrees: FactorsToday shows BD loading positively on Value, DividendYield, Quality and LowVolatility but negatively on Momentum (−0.185) and Beta (−0.304), with a 3-year annualized return of −8.5%, a 5-year of −3.3%, trading ~31% below its relative-strength peak with a ~40% max drawdown. This is a defensive value/falling-knife name, not a momentum trade — consensus has abandoned it.

The strongest bull case. BD owns irreplaceable, standard-setting franchises (Vacutainer, pre-fillable syringes serving 27/30 top pharma, Pyxis) trading at a decade-trough multiple. Three under-appreciated tailwinds compound from here: (1) the GLP-1/biologics injectable wave structurally lifts the highest-return franchise; (2) ~$1.9B/yr of Bard/CareFusion intangible amortization rolls off over the coming years, mechanically lifting GAAP ROIC and EPS; and (3) the Waters separation hands BD ~$4B to delever and shrink a float that M&A bloated. A focused, deleveraging New BD that simply holds mid-single-digit growth re-rates one-to-two turns toward Medtronic — meaningful upside from a 4th-percentile starting valuation, with a 53-year dividend paying you to wait.

The strongest bear case. The moats are real but have never reached the owner: ROIC has been stuck at ~6% for five years and there is no proof the amortization roll-off won’t simply be reinvested into the next overpriced deal. Organic growth has decelerated to sub-3%; BD just sold its best-share growth franchise (flow cytometry); the commodity-device base is squeezed by GPO/VBP/tariffs; oral GLP-1 threatens the one great tailwind; and the EtO/PowerPort torts sit largely unreserved. The “self-help” re-rating is exactly what activists and break-up optimists already paid up for in 2025 — and the Feb-2026 sell-the-news suggests the easy money has been made. This is a value trap with a nice coupon.

The 3–5 assumptions that matter most:

1. Does ROIC inflect above ~7–8%? (Amortization roll-off + deleveraging + no new overpriced M&A.) Falsifies the bull if ROIC stays ~6% through FY2027.
2. Does organic growth hold mid-single-digits? (GLP-1/biologics + Alaris recovery offsetting China/commodity pressure.) Falsifies the bull if New-BD organic stays sub-3%.
3. Is the ~$1.7B litigation reserve adequate? (PowerPort bellwethers + the EtO appellate ruling.) Falsifies the bull if a tort breaches the reserve materially.
4. Is the Waters cash deployed to delever/shrink the float, or into the next deal? Falsifies the bull if BD re-levers for another acquisition.
5. Does the multiple re-rate, or is the discount permanent? (The value-trap question.)

Where consensus may be offsides. Consensus is anchored on the past (serial disappointment, low ROIC) and the whole-company lens; it may under-weight the mechanical EPS/ROIC tailwind from amortization roll-off and the genuine quality of the GLP-1-levered BioPharma franchise inside a now-focused New BD. The factor tape — deeply out-of-favor, abandoned by momentum, cheap on value — is consistent with a name where expectations are low enough that not-disastrous execution is rewarded. But the same tape is also consistent with a value trap; the factor read tells you consensus has given up, not that it is wrong.

12. Fact vs. Interpretation Table

13. Open Questions

1. Precise China revenue % (10-K only discloses Greater Asia ~14.2%) and the run-rate VBP drag.
2. Stranded-cost quantum post-Waters and the TSA roll-off path — how much of the New-BD EPS reset is permanent vs. recoverable.
3. Bard/CareFusion intangible amortization schedule — the exact pace at which the ~$1.9B/yr drag rolls off and lifts GAAP ROIC.
4. Reconciliation of hernia claim counts — BD reports ~6,995 outstanding vs. plaintiff-side ~23,693 MDL-pending; is the ~$1.7B reserve genuinely fully loaded for the unfiled tail?
5. EtO appellate ruling (argued May-14-2026) on the punitive-cap/specific-intent question — a near-term binary.
6. Size and split of the post-separation buyback (the ~$4B Waters cash: how much delever vs. repurchase).
7. Whether the LTI’s ROIC metric uses goodwill-inclusive invested capital — if it excludes acquired goodwill, the metric flatters management.
8. Exact consumable-vs-capital revenue split (not disclosed in the 10-K).

14. What Must Be True

For the bull case to be right:

• New BD inflects ROIC above ~7–8% by FY2027–28 as Bard/CareFusion intangibles amortize off and BioPharma scales — and management does not re-lever into another overpriced deal. Falsification test: if FY2027 ROIC is still ~6% (or BD announces a >$3B acquisition funded with debt/stock), the bull thesis is broken — the moats remain real but irrelevant to owners.
• Organic revenue growth holds mid-single-digits with the GLP-1/biologics tailwind and Alaris recovery offsetting China/commodity pressure. Falsification test: two consecutive quarters of New-BD organic growth below ~3% absent a one-off would confirm the structural-stagnation bear.
• The ~$4B Waters cash is deployed to delever and shrink the float, and the ~$1.7B litigation reserve proves adequate. Falsification test: a PowerPort/EtO verdict or settlement that materially breaches the reserve.

For the bear case to be right:

• ROIC stays ~6%, organic growth stays sub-3%, and the multiple discount proves permanent — a value trap with a coupon. Falsification test: a sustained re-rating toward Medtronic’s ~14× on the back of an actual ROIC/growth inflection would break the bear.
• China VBP + oral-GLP-1 + tariffs squeeze the two best franchises (BioPharma, Vacutainer-adjacent) faster than amortization roll-off helps. Falsification test: BioPharma sustaining high-single-digit growth through FY2027 with stable margins.

The two cases pivot on a single axis: does the business’s operating quality finally reach the owner via ROIC and capital discipline, or do the moats stay walled off from shareholder returns? Everything else is detail.

15. Source Appendix

See the Source Appendix (Appendix B, below) for the full source list. Primary sources: BD FY2025 Form 10-K (filed 2025-11-25, period ended 2025-09-30); Q1 FY2026 10-Q (2026-02-09) and Q2 FY2026 10-Q (2026-05-07); DEF 14A proxy (2025-12-18); Form 4 corpus (CIK 0000010795); 8-Ks (Starboard/separation 2025-02-05, Augusta SpinCo 2026-02-05, debt 2026-05); BD investor-relations press releases and earnings-call transcripts (Q1/Q2 FY2026); SEC EDGAR XBRL; ROIC.ai (ratios, enterprise value, valuation multiples, statements — reconciled to filings); AZI price series and own-history valuation percentiles; FactorsToday factor model; and named third-party industry sources (market-sizing publishers for pre-fillable syringes, flow cytometry, dispensing) and trade/legal press (CNBC, Law.com, National Law Review, MDL trackers), each cited inline at point of use. All figures reconcile to BD’s filings unless explicitly flagged as estimate or interpretation.

APPENDIX A — Standard Diligence Questionnaire

Becton, Dickinson and Company (NYSE: BDX) — as of 2026-06-19

Supplemental to the research memo. Fact / Interpretation / Assumption labeled where material.

General

What thoughtful questions have other investors asked about this company? The central question every BDX investor asks is some version of: “Why does a business with 36–43% segment operating margins and category leadership in nearly everything it sells earn only ~6% ROIC and trade at a decade-trough multiple?” The answer — that BD overpaid for its moats (CareFusion, Bard, Edwards) and buried them under ~$36B of goodwill/intangibles — frames every other question. Related recurring questions: Will the Waters separation actually create value or just shuffle it? Is the dividend safe (yes — 53-year streak, ~30% of adjusted EPS)? How much of “adjusted” EPS is real vs. amortization gimmickry? Is this a value trap? And what is the true tail risk in the Bard hernia/PowerPort and EtO litigation?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Neither extreme. Revenue is defensive and recurring (consumables/devices into hospitals); volumes are not very cyclical. Margins are arguably below mid-cycle — recovering from Alaris-recall and inflation drags, now absorbing a structural ~160 bps tariff hit. Interpretation: earnings power is mid-cycle-to-slightly-depressed, not peak. Driven by external environment or internal actions? Predominantly internal — the story is self-help (separations, deleveraging, margin programs, Alaris recovery) layered over a stable external demand environment, with external headwinds (China VBP, tariffs, FX) acting as offsets. How stable are revenues? Highly stable; the large majority is recurring single-use consumables and installed-base pull-through. Quarter-to-quarter organic growth is low-but-steady (sub-3% to mid-single-digit). Outlook for products/services? Mixed: structural tailwind in pre-fillable syringes (GLP-1/biologics); recovery in Alaris; double-digit pockets (PureWick, APM/Edwards, pharmacy automation); persistent pressure in commodity devices and (departed) Diagnostics. How big is this market — growing, shrinking, domestic or international? Global MedTech is ~$500B+, growing mid-single-digits; ~41% of BD revenue is ex-US. BD’s best niche (pre-fillable syringes, ~$8.7B→~$18B by 2033, ~9.7% CAGR) grows fastest; its commodity base grows slowest.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More, at the buy side — hospital/IDN/GPO consolidation increases purchasing power; China VBP intensifies commodity pricing pressure. Less, in the protected niches (Vacutainer standard, pre-fillable regulatory lock-in) where structure is stable. How profitable is the business (ROIC, ROE)? Operating: excellent (36–43% segment margins). Capital: poor — ROIC ~5.9%, ROE ~10%, ROA ~3% (FY2025), because of acquisition goodwill/intangibles. This is the defining tension. How profitable is the industry — competitors, barriers? MedTech is structurally profitable with high regulatory barriers (FDA 510(k)/PMA, EU MDR/IVDR). Competitors: Medtronic, Abbott, Stryker, Boston Scientific, Edwards, Baxter, ICU Medical, Thermo Fisher, Danaher, Gerresheimer, West Pharmaceutical. Can it be easily understood? Yes at the franchise level; the complexity is in the goodwill-laden balance sheet and the constant portfolio reshaping. Undermined by foreign low-cost labor? Partly — the commodity-syringe/needle end faces low-cost competition and China VBP; the standard-setting and regulatory-locked franchises are insulated. Do brands matter? Yes in a functional, B2B sense — BD Vacutainer, Pyxis, Alaris, ChloraPrep, PureWick are trusted institutional standards with validation/workflow lock-in, not consumer brands. Nature of competition? Scale, breadth, installed base, regulatory qualification, and price on the commodity end. Customers’ switching costs? High in Pyxis/Alaris (workflow + IT integration), pre-fillable syringes (re-filing), and Vacutainer (lab re-validation); low in commodity consumables.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The brand/standard value of Vacutainer and the regulatory-qualified pre-fillable franchise are worth more than carried; conversely, much of the ~$36B goodwill/intangibles is arguably over-stated relative to the returns it generates. Off-balance-sheet liabilities? Operating leases (capitalized under ASC 842); the litigation tail beyond the ~$1.7B reserve (EtO/PowerPort largely unreserved) is the real off-balance-sheet risk. TSA/stranded-cost obligations from the Waters separation. How conservative is the accounting? Mixed — the $175M SEC disclosure settlement (2024) and an engaged independent compliance consultant are a yellow flag; “adjusted” EPS strips out large, recurring amortization. Interpretation: read GAAP and adjusted together; trust neither alone. How CapEx-hungry? Moderate — capex ~$0.9B/yr (~4% of sales), typical for a consumables manufacturer; not asset-light, not heavy.

Capital Allocation & Management

How much FCF, and how is it used? ~$2.5B FCF in FY2025; uses: ~$1.2B dividend (priority #1), debt service/paydown, ~$1B buybacks (restarted under activist pressure), and bolt-on M&A. Interpretation: dividend is well-managed; the historical M&A was value-destructive; buybacks are belatedly increasing. Significant acquisitions recently? Edwards Critical Care ($3.914B, Sept-2024). The larger story is divestiture: embecta (2022) and the Waters RMT (closed Feb-2026). Buying back shares? Yes, increasingly ($0→$500M→$1.0B FY23→25, continuing FY26 with Waters cash), but a decade of M&A net added ~25M shares. Issuing shares to insiders? SBC ~$258M/yr (~1.2% of revenue) — modest; the big dilution was the Bard stock consideration, not ongoing grants. Compensation of directors/management? CEO Polen ~$17.1M (stable). LTI includes ROIC (50% of PSUs) and relative TSR — good design — but Revenue/adjusted-EPS weightings and a 137% PSU payout amid ~6% ROIC suggest soft targets. Motivations of management? Interpretation: the reshaping (sell down the conglomerate, focus, return cash) is shareholder-friendly in direction; the open question is whether the ~$4B Waters cash goes to deleveraging/buybacks or another deal.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — ordinary US common stock, standard 1099 dividends. Dividend policy? Dividend King, 53+ consecutive annual increases; $4.16/sh FY2025; ~2.6% yield; ~30% of adjusted EPS — well-covered and a genuine floor. How profitable is the business? See above — operationally very, on capital poorly. Is net income diverging from cash from operations? Yes, structurally — OCF (~$3.4B) is ~2× net income (~$1.7B) because of the large non-cash amortization add-back. This is mechanical, not a red flag, but it is why GAAP earnings understate cash economics.

Risks & Downside

What would cause the stock to decline? A growth/ROIC failure-to-inflect (value trap); an EtO/PowerPort litigation surprise breaching the reserve; an FDA escalation of the open Warning Letters (ChloraPrep supply); a debt-funded acquisition that re-levers; or a broad MedTech de-rating. Risk of catastrophic loss? Low — diversified, investment-grade, cash-generative, fortress dividend. The realistic downside is multi-year dead-money plus litigation cash bleed, not impairment of the going concern. Chance of total loss? Very low absent an unforeseeable balance-sheet shock.

Recent News & Events

Has the business environment changed recently? Materially — the Waters separation closed Feb-9-2026, creating a focused “New BD” with a reset (~$12.6) EPS base. Starboard is engaged; the Edwards Critical Care deal closed Sept-2024; the Alaris recall is behind the company; tariffs are a new ~160 bps drag. Significant acquisitions? Edwards Critical Care (2024); offset by the Waters/embecta divestitures. Change in accounting policies? Segment realignment (FY2026, four New-BD segments); separation accounting (discontinued operations) drove a GAAP net loss in Q2 FY26. No adverse policy change flagged beyond the prior SEC disclosure-controls matter. Recent changes — new markets, facilities, management? $110M US pre-fillable-syringe capacity investment (Jan-2026); CEO/Chairman Polen continues; new international structure post-separation.

APPENDIX B — Source Appendix

Becton, Dickinson and Company (NYSE: BDX) — as of 2026-06-19

All facts in the memo trace to the sources below. Primary (filings, company disclosures) prioritized over secondary; secondary used for qualitative/industry context and litigation tracking. Accessed 2026-06-19 unless noted.

Primary — SEC filings (EDGAR, CIK 0000010795)

1. BD Form 10-K, FY2025 — filed 2025-11-25, period ended 2025-09-30. Revenue/segment/geography detail (Note 8), commitments & contingencies (litigation reserve), debt/credit ratings, Waters RMT disclosure (Note 1), Edwards/APM purchase accounting (Note 11), regulation. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000010795&type=10-K
2. BD Form 10-Q, Q2 FY2026 — filed 2026-05-07, period ended 2026-03-31. New-BD segment view, ~$1.7B litigation accrual (3/31/26), hernia/PowerPort/EtO claim counts, El Paso Warning Letter, tariff/China commentary, GAAP net loss.
3. BD Form 10-Q, Q1 FY2026 — filed 2026-02-09, period ended 2025-12-31. New-BD guidance introduction; Waters close.
4. BD Form 10-Ks, FY2021–FY2024 — multi-year revenue, margin, debt, share-count, dividend history.
5. DEF 14A proxy — filed 2025-12-18. CEO comp ($17.1M), PIP/LTI metric weights (Revenue/adj-EPS/Op-Margin/FCF; PSU Revenue-Growth/ROIC + rel-TSR), 137% 2022–24 PSU payout, ~89% say-on-pay.
6. Form 4 corpus (CIK 0000010795), ~120 filings June-2024–June-2026 — insider transactions: two director open-market buys (Hayes 5,250@$191.57 Aug-2025; Henderson 1,500@$233.62 Feb-2025); no CEO/CFO open-market buys.
7. 8-Ks — Starboard/separation announcement (2025-02-05); Augusta SpinCo formation (2026-02-05); €600M 3.855% notes due 2033 (2026-05-12/05-20); Form 25-NSE (2026-06).

Primary — company disclosures

8. BD Q4/FY2025 earnings release — FY2025 adjusted EPS $14.40, organic +2.9%. investors.bd.com.
9. BD Q2 FY2026 earnings release (2026-05-07) — adj EPS $2.90, adj op margin 24.2%, guidance raise to $12.52–$12.72. https://investors.bd.com/news-events/press-releases/detail/958
10. BD Q1 FY2026 earnings release (2026-02-09) — New-BD guide $12.35–$12.65. https://www.prnewswire.com/news-releases/bd-reports-first-quarter-fiscal-2026-financial-results-302681727.html
11. BD/Waters Reverse Morris Trust announcement (2025-07-13/14) — ~$17.5B; BD holders ~39.2%; ~$4B cash to BD.
12. BD $110M pre-fillable-syringe capacity investment (2026-01-13). https://news.bd.com/2026-01-13-BD-Announces-110-Million-to-Support-U-S-Pharmaceutical-Supply-Chain-for-Biologic-Drugs
13. BD historical M&A releases — C.R. Bard ($24B/$317-share, 2017-04-23, release #403); CareFusion (2014-10-05, release #534); Parata Systems ($1.525B, 2022-07-18); Edwards Critical Care close (2024-09-03).
14. BD earnings-call transcripts — Q1 FY2026 (2026-02-09), Q2 FY2026 (2026-05-07) — via ROIC.ai and public transcript (Motley Fool).

Quantitative data services

15. SEC EDGAR XBRL — authoritative US-filer financial facts; share count, debt, dividends, goodwill/intangibles.
16. ROIC.ai — income statement/balance sheet/cash flow (FY2020–FY2025), profitability ratios (ROIC/ROE/ROA), enterprise value, 11-year valuation multiples; peer EV/EBITDA (MDT 14.7×, ABT 19.0×, BSX 18.7×, SYK 21.7×, BAX 14.1×). Third-party aggregated; reconciled to filings.
17. AZI — split/dividend-adjusted price series (5-year event map anchors) and own-history valuation-index percentiles (P/S 4th, P/B 7th, composite 24th percentile).
18. FactorsToday factor model — factor loadings (+Value/+DividendYield/+Quality/+LowVol, −Momentum −0.185, −Beta −0.304), beta 0.47, leaderboard (3yr ann −8.5%, 5yr −3.3%, ~31% below RS peak, ~40% max drawdown).

Secondary — industry & market sizing

19. Pre-fillable syringe market (~$8.7B→~$18B by 2033, ~9.7% CAGR; BD #1) — MarketsandMarkets, Grand View Research.
20. Flow cytometry (~$5.1B, ~8.7% CAGR; BD leader) — GlobeNewswire/Coherent Market Insights.
21. Automated medication dispensing (Pyxis ~22–26% share) — Mordor Intelligence, Future Market Insights.
22. Blood-collection-tube market (~6% CAGR; BD dominant) — Precedence Research, Mordor Intelligence.

Secondary — litigation & news

23. C.R. Bard PowerPort first bellwether defense verdict (2026-05-08) — Law.com; aboutlawsuits.com.
24. Hernia mesh MDL 2846 status — mdlupdate.com; drugwatch.com; sokolovelaw.com.
25. EtO Georgia $20M Walker verdict / punitive mistrial; appeal argued 2026-05-14 — National Law Review; 11Alive; topclassactions.com.
26. Alaris 510(k) clearance (2023-07) — Healio. SEC $175M Alaris disclosure settlement (2024-12) — Cooley PubCo.
27. Starboard stake & separation — CNBC (2025-02-08).
28. C.R. Bard ~21.4× EBITDA acquisition multiple — BSIC; CNBC (2017-04-23).